Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

FOSRENOL

LANTHANUM CARBONATE

Standard Dose
EQ 250MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview FOSRENOL is listed in Drugs@FDA under application 021468 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LANTHANUM CARBONATE Form and strength TABLET, CHEWABLE;ORAL - EQ 250MG BASE Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-08-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview FOSRENOL is listed in Drugs@FDA under application 021468 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LANTHANUM CARBONATE Form and strength TABLET, CHEWABLE;ORAL - EQ 250MG BASE Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-08-29 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.